Research shows immune system response is detrimental to novel brain cancer therapy
For the first time, researchers have demonstrated that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel way of treating malignant brain cancer by injecting a virus into the tumor. A number of clinical trials are currently underway to test whether glioblastoma virotherapy will facilitate antitumor efficacy, but new research shows that in pre-clinical models, NK cells are killing off the virus – infected cells, thus rendering the therapy less effective.
